News & Events

• Genetic Analysis presents at Mangold Insight’s Investor Day
  Published on 2023-03-17
• Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
  Published on 2023-03-09
• Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
  Published on 2023-03-07
• Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
  Published on 2023-02-28
• Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
  Published on 2023-02-27
• Year-end report January – December 2022
  Published on 2023-02-17
• Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
  Published on 2023-02-14
• Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
  Published on 2023-02-08
• Genetic Analysis strengthens and future-proofs the organization
  Published on 2023-01-31
• Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
  Published on 2023-01-27
• Genetic Analysis AS achieves Thai FDA License for GA-map[®] Dysbiosis Test in Thailand
  Published on 2023-01-19
• Genetic Analysis AS achieves Thai FDA License for GA-map® Dysbiosis Test in Thailand
  Published on 2023-01-19
• Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map[®] technology in India
  Published on 2023-01-16
• Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map® technology in India
  Published on 2023-01-16
• Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Published on 2023-01-13